Cast Bio Overview

  • Year Founded
  • 2026

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Seed
  • (Upcoming)

  • Investors
  • 2

Cast Bio General Information

Description

Operator of an antibody-drug conjugate company intended to treat refractory cancers. The company's technology utilizes a proprietary cancer stromal targeting method and specialized linker technology to deliver therapeutic agents to difficult-to-treat tumors, enabling pharmaceutical partners to advance drug discovery for glioblastoma and pancreatic cancer.

Contact Information

Website
castbio.co.jp
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Ginza East Building 2Floor
  • 1-13-10 Tsukiji, Chuo-ku
  • Tokyo
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Ginza East Building 2Floor
  • 1-13-10 Tsukiji, Chuo-ku
  • Tokyo
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cast Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round Upcoming Startup
2. Seed Round 18-May-2026 Completed Startup
1. University Spin-Out 30-Mar-2026 Completed Startup
To view Cast Bio’s complete valuation and funding history, request access »

Cast Bio Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Cast Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4130269-A1 Fibrin-binding antibody and pharmaceutical composition containing antibody Pending 31-Mar-2020
EP-4130269-A4 Fibrin-binding antibody and pharmaceutical composition containing antibody Pending 31-Mar-2020
US-12600797-B2 Fibrin-binding antibody and pharmaceutical composition containing antibody Active 31-Mar-2020
US-20230132177-A1 Fibrin-binding antibody and pharmaceutical composition containing antibody Active 31-Mar-2020
EP-4129334-A1 Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein Pending 31-Mar-2020 C07K16/18
To view Cast Bio’s complete patent history, request access »

Cast Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cast Bio Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
UntroD Venture Capital Minority
RIN Institute VC-Backed Company
To view Cast Bio’s complete investors history, request access »

Ready to get started?

Request a free trial

Cast Bio FAQs

  • When was Cast Bio founded?

    Cast Bio was founded in 2026.

  • Where is Cast Bio headquartered?

    Cast Bio is headquartered in Tokyo, Japan.

  • What is the size of Cast Bio?

    Cast Bio has 3 total employees.

  • What industry is Cast Bio in?

    Cast Bio’s primary industry is Drug Discovery.

  • Is Cast Bio a private or public company?

    Cast Bio is a Private company.

  • What is Cast Bio’s current revenue?

    The current revenue for Cast Bio is .

  • Who are Cast Bio’s investors?

    UntroD and RIN Institute have invested in Cast Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process